AR036331A1 - Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores - Google Patents

Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores

Info

Publication number
AR036331A1
AR036331A1 ARP020101576A ARP020101576A AR036331A1 AR 036331 A1 AR036331 A1 AR 036331A1 AR P020101576 A ARP020101576 A AR P020101576A AR P020101576 A ARP020101576 A AR P020101576A AR 036331 A1 AR036331 A1 AR 036331A1
Authority
AR
Argentina
Prior art keywords
inhibitors
intermediaries
procedure
development
useful compounds
Prior art date
Application number
ARP020101576A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR036331A1 publication Critical patent/AR036331A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

El compuesto es éster etílico del ácido (2R,4S)-2-etil-4-metoxicarbonilamino-6-trifluormetil-3,4-dihidro-2H-quinolina-1-carboxílico de fórmula (1) útil como intermediario para la síntesis de inhibidores de la proteína de transferencia del éster de colesterilo (CETP). También se dan a conocer los procedimientos para obtener dichos intermediarios e inhibidores.
ARP020101576A 2001-04-30 2002-04-29 Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores AR036331A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
AR036331A1 true AR036331A1 (es) 2004-09-01

Family

ID=23103272

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP020101576A AR036331A1 (es) 2001-04-30 2002-04-29 Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores
ARP020101575A AR035963A1 (es) 2001-04-30 2002-04-29 Compuestos derivados de trifluormetilbenceno utiles como intermedios de los inhibidores de la proteina de transferencia del ester de colesterilo y procedimientos para su preparacion
ARP040102071A AR044706A2 (es) 2001-04-30 2004-06-15 Procedimientos para preparar 4-aminoquinolinas, inhibidores de cetp

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP020101575A AR035963A1 (es) 2001-04-30 2002-04-29 Compuestos derivados de trifluormetilbenceno utiles como intermedios de los inhibidores de la proteina de transferencia del ester de colesterilo y procedimientos para su preparacion
ARP040102071A AR044706A2 (es) 2001-04-30 2004-06-15 Procedimientos para preparar 4-aminoquinolinas, inhibidores de cetp

Country Status (25)

Country Link
US (3) US6689897B2 (es)
EP (2) EP1383734B1 (es)
JP (2) JP3924251B2 (es)
KR (2) KR100639745B1 (es)
CN (3) CN100357265C (es)
AR (3) AR036331A1 (es)
AT (2) ATE321755T1 (es)
AU (1) AU2002253448B2 (es)
BR (2) BR0209291A (es)
CA (2) CA2445623A1 (es)
CZ (2) CZ20032900A3 (es)
DE (2) DE60210265T2 (es)
DK (2) DK1425270T3 (es)
ES (2) ES2256461T3 (es)
HK (1) HK1062294A1 (es)
HU (2) HUP0304039A3 (es)
IL (2) IL157544A0 (es)
MX (2) MXPA03009936A (es)
PL (2) PL366584A1 (es)
PT (1) PT1425270E (es)
RU (2) RU2265010C2 (es)
TW (1) TWI250974B (es)
WO (2) WO2002088085A2 (es)
YU (2) YU84303A (es)
ZA (2) ZA200306599B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
BR0315041A (pt) * 2002-10-04 2005-08-16 Millennium Pharm Inc Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica
ATE407670T1 (de) 2002-12-20 2008-09-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US7601842B2 (en) 2003-02-18 2009-10-13 Takasago International Corporation Method for producing an optically active tetrahydroquinoline
EP1604975A4 (en) * 2003-03-17 2006-11-02 Kaneka Corp PROCESSES FOR PRODUCING (R) -3- 4- (TRIFLUOROMETHYL) -PHENYLAMINO-PENTANAMIDE DERIVATIVES
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
RU2330682C2 (ru) 2003-09-26 2008-08-10 Джапан Тобакко Инк. Способ ингибирования продуцирования остаточных липопротеинов
EP2098512A1 (en) * 2003-10-08 2009-09-09 Eli Lilly & Company Compounds and methods for treating dyslipidemia
DE602004020649D1 (de) * 2003-11-07 2009-05-28 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
JP2007532555A (ja) * 2004-04-07 2007-11-15 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患の処置のためのｐｇｄ２レセプターアンタゴニスト
WO2006012093A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
MX2007010215A (es) 2005-02-24 2007-11-07 Millennium Pharm Inc Antagonistas del receptor pgd2 para el tratamiento de enfermedades inflamatorias.
US20100041911A1 (en) * 2005-06-20 2010-02-18 Astrazeneca Ab Process For The Production Of (Alkoxycarbonylamino)alkyl Sulfonates
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
KR101442644B1 (ko) 2011-04-12 2014-09-19 주식회사 종근당 Ｃｅｔｐ 억제제로서의 사이클로알케닐 아릴 유도체
CA2841117A1 (en) 2011-07-08 2013-01-17 Novartis Ag 1,2-disubstituted-4-benzylamino-piperidinyl derivatives as cetp inhibitors useful for the treatment of atherosclerosis in high triglyceride subjects
BR112015018442B1 (pt) 2013-01-31 2022-09-06 Chong Kun Dang Pharmaceutical Corp. Compostos de derivados de ciclohexeno biaril- ou heterocíclico biaril-substituídos, composições farmacêuticas e uso
CN105706289A (zh) * 2013-11-11 2016-06-22 隆萨有限公司 利用路易斯酸制备第13族元素的氰基化合物的方法
CN107108558B (zh) * 2014-08-12 2019-11-19 狄智玛制药私人有限公司 制备用于制备四氢喹啉衍生物的合成中间体的方法
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69929609T2 (de) 1998-07-10 2006-09-28 Massachusetts Institute Of Technology, Cambridge Liganden für metalle und metall-katalysiertes verfahren
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
WO2002088069A2 (en) 2002-11-07
CN1529696A (zh) 2004-09-15
WO2002088085A3 (en) 2004-03-25
CA2445693A1 (en) 2002-11-07
ES2259080T3 (es) 2006-09-16
AU2002253448B2 (en) 2007-07-05
HUP0304041A3 (en) 2005-08-29
DK1383734T3 (da) 2006-05-15
YU84303A (sh) 2006-05-25
KR100639745B1 (ko) 2006-10-30
CN1505609A (zh) 2004-06-16
HK1062294A1 (en) 2004-10-29
RU2003131870A (ru) 2005-01-27
CN100357265C (zh) 2007-12-26
TWI250974B (en) 2006-03-11
JP2004527556A (ja) 2004-09-09
MXPA03009935A (es) 2004-01-29
MXPA03009936A (es) 2004-01-29
US6689897B2 (en) 2004-02-10
HUP0304041A2 (hu) 2004-04-28
KR100591998B1 (ko) 2006-06-22
WO2002088069A3 (en) 2003-02-20
AR044706A2 (es) 2005-09-21
DE60210265D1 (de) 2006-05-18
JP3924251B2 (ja) 2007-06-06
RU2265010C2 (ru) 2005-11-27
ZA200306600B (en) 2004-08-25
EP1383734A2 (en) 2004-01-28
CZ20032898A3 (cs) 2004-07-14
DE60209004T2 (de) 2006-09-28
HU225777B1 (en) 2007-08-28
WO2002088085A2 (en) 2002-11-07
RU2003131871A (ru) 2005-04-10
BR0209291A (pt) 2004-07-13
IL157544A0 (en) 2004-03-28
CN1267411C (zh) 2006-08-02
DE60209004D1 (de) 2006-04-13
US20030216576A1 (en) 2003-11-20
ATE316957T1 (de) 2006-02-15
KR20040015200A (ko) 2004-02-18
AR035963A1 (es) 2004-07-28
CZ20032900A3 (cs) 2004-06-16
HUP0304039A2 (hu) 2004-03-29
ATE321755T1 (de) 2006-04-15
JP2004531541A (ja) 2004-10-14
ES2256461T3 (es) 2006-07-16
CA2445623A1 (en) 2002-11-07
HUP0304039A3 (en) 2005-10-28
JP3924250B2 (ja) 2007-06-06
EP1425270B1 (en) 2006-03-29
EP1425270A2 (en) 2004-06-09
DK1425270T3 (da) 2006-07-03
US6706881B2 (en) 2004-03-16
PL366584A1 (en) 2005-02-07
CN1297541C (zh) 2007-01-31
DE60210265T2 (de) 2006-10-12
ZA200306599B (en) 2004-10-22
PL366700A1 (en) 2005-02-07
PT1425270E (pt) 2006-07-31
US20020177716A1 (en) 2002-11-28
US6600045B2 (en) 2003-07-29
IL157546A0 (en) 2004-03-28
EP1383734B1 (en) 2006-02-01
WO2002088069A9 (en) 2003-12-04
CN1680292A (zh) 2005-10-12
KR20040030603A (ko) 2004-04-09
RU2259355C2 (ru) 2005-08-27
BR0209238A (pt) 2004-06-15
US20030073843A1 (en) 2003-04-17
YU84403A (sh) 2006-08-17

Similar Documents

Publication Publication Date Title
AR036331A1 (es) Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores
FR17C0003I2 (fr) Steroides comme agonistes de fxr
CR8530A (es) Intermediarios de quinolona como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos
EA200100451A1 (ru) Замещенные аналоги бензопирана для лечения воспаления
BR0115580A (pt) Derivados de 3-aroilindol e a utilizaçao dos mesmos como agonistas dos receptores cb2
ATE359786T1 (de) Camptothecin derivate
ES2150808T3 (es) Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.
AR002711A1 (es) Un compuesto de 2-carboxindol-3-substituido,un proceso para su preparacion, un nuevo compuesto intermediario para dicho proceso, el uso del compuesto parala fabricacion de un agente terapeutico y una composicion farmaceutica que comprende dicho compuesto.
AR016175A1 (es) Compuestos derivados del acido dihidroxihexanoico, su uso para la preparacion de medicamentos y composiciones de los mismos.
TR200400857T4 (tr) Yeni galantamın türevleri ve analogları
PT775117E (pt) Analogos de 2-nitroimidazole fluorinados para detectar celulas de tumor hipoxicas
ES532147A0 (es) 1h-imidazol-1-etanol y esteres derivados del mismo, asi como procedimiento para su obtencion
ES496038A0 (es) Procedimiento para la obtencion de 2-hidroxialquil-3,4,5- trihidroxi-piperidinas
AR006058A1 (es) Procedimientos para preparar compuestos de dicianoacetato y de 1,2-pirazol-5-amino-3-substituido
BRPI0409154A (pt) processo para a preparação de 5-(haloacetil)-8-(óxi substituìdo)-(1h)-quinolin-2-onas
EA200400806A1 (ru) Способ получения эхинокандиновых соединений
EA199900204A1 (ru) Способы и промежуточные соединения для получения замещенных производных хроманола
FI875596A (fi) Foerfarande foer framstaellning av tienyletylaminer och aeven ditienyletylaminer.
BRPI0416678A (pt) pirazolpirimidinas
BR9912870A (pt) Processo para sìntese de derivados de (1h) - benzo (c)quinolizina-3-onas
ATE416174T1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
ATE9225T1 (de) Derivate des 5-hydroxy-tetrahydro-2-furanons.
BR0110805A (pt) Processo para a preparação de compostos de anilina
MX163460B (es) Procedimiento para la preparacion de diazaoxaespirodecanos substituidos y empleo como estabilizadores para polimeros
FI963168A (fi) Enkefalinaasin inhibiittoreina käyttökelpoisia uusia indaani-2-merkaptoasetyyliamiddisulfidijohdannaisia

Legal Events

Date Code Title Description
FB Suspension of granting procedure